Genzyme and Cystic Fibrosis Foundation Therapeutics announce collaboration on the discovery of new drugs against fibrosis cystic.
will be checked for potential therapies targeting the most common mutation of the disease.
Cambridge and Bethesda (USA.)(UU.), 2011-December Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Cystic Fibrosis Foundation Therapeutics Inc., subsidiary non-profit of the Cystic Fibrosis Foundation, have reached an agreement of research to support the discovery of new drugs for the treatment of people with the most common mutation for cystic fibrosis: Delta F508.
Patients with cystic fibrosis experience a cascade of symptoms which can cause serious lung infections and premature death. The objective of the programme is to identify compounds correction ” that can contribute to the better functioning of the defective protein found in these patients, the CFTR. In the Delta F508 mutation, the CFTR protein is not located in its rightful place of the cell surface, preventing the flow of fluid into the airway. Almost 90% of patients with cystic fibrosis have at least one copy of the Delta F508 mutation.
The collaboration implies that the investigators will evaluate various chemical libraries of correction ” of Delta F508 and take advantage of Genzyme and Sanofi. The research will take place in various international centres of r & d of Genzyme and Sanofi. Genzyme brings to the agreement for more than 20 years of experience in research into therapies for patients with cystic fibrosis. The company’s efforts ranging from the improvement of the molecular diagnosis to clinical trials with gene therapy, including previous collaborations with the Cystic Fibrosis Foundation.
We are pleased to begin this research collaboration with Genzyme, a laboratory dedicated long time to improve the lives of people with rare diseases ”, says Dr. Robert j. Beall, President and Chief Executive Officer of the foundation of Fibrosis cystic. the capacities and resources of Genzyme will help the Cystic Fibrosis Foundation to accelerate their efforts in the discovery of fármacos for the treatment of the most common mutation of the disease ”.
Even though they have been giving great advances in cystic fibrosis research, still having many needs to be filled ”, adds CEO of Genzyme, Dr. David Meeker. along with the Cystic Fibrosis Foundation hope to accelerate the pace of discoveries for the benefit of patients suffering from this disease around the world ”.
Cystic Fibrosis Foundation about
the Cystic Fibrosis Foundation is an international leader in research for a cure for the disease. The Foundation funds more research about cystic fibrosis than any other organization and almost all currently available medications have been made possible thanks to your support. Headquartered in Bethesda (USA.)(UU.), the Foundation also supports and credited to a network of centres of assistance that it has earned the recognition of the national institutes of health as a model for treatment of a chronic disease. The Cystic Fibrosis Foundation is a non-profit funded through donations.
on Genzyme, a company of Sanofi
since our founding in 1981, Genzyme we’ve inspired in patients with serious illnesses, with the aim of causing the biggest positive impact on their lives. Today we are one of the leading companies in biotechnology, with approximately 10,000 employees serving patients in 100 countries. Genzyme is a company of Sanofi.
About Sanofi
Sanofi, a diversified and global leader in the field of health care, discovers, develops and distributes therapeutic solutions focusing on the needs of patients. Sanofi has its main strength in the care of health with seven areas of growth: solutions in the area of diabetes, vaccines, innovative medicines, rare diseases, pharmacy and the health care, emerging markets and animal health. Sanofi is listed on the Paris Stock Exchange (EURONEXT: SAN) and in the New York Stock Exchange (NYSE: SNY).
